Technology

Antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) are not only the main ways for the body to clear cells infected by viruses or other pathogens through antibodies but also one of the mechanisms of action of current antibody drugs to exert clinical effects. Monoclonal antibody drugs link targeted therapy and immunoactivation therapy, bringing profound changes to the treatment of cancer. In particular, in ADCC, the Fab fragment of the antibody can target tumors, infected cells, or free pathogens, and its Fc fragment can bind to FcγR, which has effector activity, making it have strong immunological activity. Creative Biolabs develops multiple ADCC/CDC platforms to facilitate your research projects:

ADCC Enhancement Technology Creative Biolabs provides proprietary ADCC enhancement technology to help you target different diseases of your interests and accelerate your research. We have different platforms for your project to meet your different needs, including Afuco™, Glymax™, Fucoanalog™, Fc Protein-Engineering, Cross-Isotype Engineering, CD16A Bispecific Antibody Engineering, and Glyco- and Fc Protein Dual Engineering. Click to Learn More

CDC Enhancement Technology Creative Biolabs is committed to developing and promoting the field of CDC-enhanced antibodies. In this section, we have proprietary CDC⁺ antibody platform, including Crea-Tag™, Fc Protein Engineering, and Crosstype™ Engineering, which allows antibody conversion with limited or no chance to mutate to other potent cytotoxic antibodies. Click to Learn More

Dual ADCC/CDC Enhancement Technology With a dedicated team and its advanced knowledge of ADCC/CDC enhancement technology, Creative Biolabs integrates ADCC and CDC dual enhancement modifications into a single antibody platform, providing a proprietary ADCC/CDC⁺ dual antibody platform for the design and development of dual ADCC/CDC enhanced antibodies with enhanced ADCC and CDC activity. Click to Learn More

Therapeutic Fc Engineering Technology Crystallizable region (Fc) enhances the efficacy of monoclonal antibodies by functioning such as ADCC, ADCP, and CDC. Creative Biolabs is committed to the design of Fc receptor-IgG interacting biologics. We offer you a variety of innovative Fc modification strategies to facilitate your projects. Click to Learn More

Therapeutic Antibody Glycosylation Engineering Technology Creative Biolabs develops engineered Fc glycosylation to produce therapeutic monoclonal antibodies with desired properties to enhance the function and efficacy of therapeutic IgG antibodies. We developed multiple glycan engineering strategies to reduce mAb glycan heterogeneity to improve the safety and therapeutic efficacy of these important drugs. Click to Learn More

With a professional team of experts who have a deep understanding of ADCC and advanced instruments and equipment, Creative Biolabs offers you full-scale technology services for your ADCC project. We are pleased to discuss our knowledge about your current problems and propose solutions to meet your requirements. Please do not hesitate to contact us.

References

1. Ma, Bo, et al. "Protein glycoengineering: An approach for improving protein properties." Frontiers in Chemistry 8 (2020): 622.
2. Zent, Clive S., et al. "Complement activation in the treatment of B-cell malignancies." Antibodies 9.4 (2020): 68.
3. Barth, Matthew J., and Stanton C. Goldman. "Resistance to Monoclonal Antibody Therapeutics in Lymphoma." Resistance to Targeted Therapies in Lymphomas (2019): 27-55.
4. Saxena, Abhishek, and Donghui Wu. "Advances in therapeutic Fc engineering–modulation of IgG-associated effector functions and serum half-life." Frontiers in immunology 7 (2016): 580.
5. Lippold, Steffen, et al. "Proteoform-resolved FcɤRIIIa binding assay for fab glycosylated monoclonal antibodies achieved by affinity chromatography mass spectrometry of Fc moieties." Frontiers in Chemistry 7 (2019): 698.